Semanteon Capital Management LP Makes New $1.18 Million Investment in Blueprint Medicines Co. (NASDAQ:BPMC)

Semanteon Capital Management LP purchased a new position in shares of Blueprint Medicines Co. (NASDAQ:BPMC) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 12,758 shares of the biotechnology company’s stock, valued at approximately $1,177,000.

Several other hedge funds also recently modified their holdings of the stock. Xponance Inc. bought a new stake in shares of Blueprint Medicines in the 4th quarter valued at $378,000. Federated Hermes Inc. bought a new stake in shares of Blueprint Medicines in the 4th quarter valued at $2,218,000. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Blueprint Medicines by 10.9% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 13,369 shares of the biotechnology company’s stock valued at $1,233,000 after acquiring an additional 1,314 shares in the last quarter. Strs Ohio increased its stake in shares of Blueprint Medicines by 94.3% in the 4th quarter. Strs Ohio now owns 6,800 shares of the biotechnology company’s stock valued at $627,000 after acquiring an additional 3,300 shares in the last quarter. Finally, Mutual of America Capital Management LLC increased its stake in shares of Blueprint Medicines by 16.6% in the 4th quarter. Mutual of America Capital Management LLC now owns 36,602 shares of the biotechnology company’s stock valued at $3,376,000 after acquiring an additional 5,204 shares in the last quarter.

Insider Buying and Selling

In related news, insider Christopher K. Murray sold 5,000 shares of the business’s stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $100.00, for a total value of $500,000.00. Following the transaction, the insider now directly owns 24,495 shares of the company’s stock, valued at approximately $2,449,500. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In related news, Director Jeffrey W. Albers sold 25,073 shares of the business’s stock in a transaction dated Wednesday, March 20th. The stock was sold at an average price of $87.28, for a total value of $2,188,371.44. Following the sale, the director now directly owns 176,050 shares in the company, valued at approximately $15,365,644. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Christopher K. Murray sold 5,000 shares of the business’s stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $100.00, for a total value of $500,000.00. Following the completion of the sale, the insider now owns 24,495 shares in the company, valued at $2,449,500. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 92,289 shares of company stock valued at $8,314,163. 3.88% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on BPMC. Wedbush reiterated an “outperform” rating and issued a $97.00 price objective on shares of Blueprint Medicines in a research note on Monday, February 5th. Barclays boosted their price target on shares of Blueprint Medicines from $58.00 to $70.00 and gave the company an “equal weight” rating in a research note on Tuesday, February 13th. Citigroup boosted their price target on shares of Blueprint Medicines from $54.00 to $65.00 and gave the company a “sell” rating in a research note on Friday, February 16th. Needham & Company LLC restated a “buy” rating and set a $97.00 price target on shares of Blueprint Medicines in a research note on Monday, February 26th. Finally, Stifel Nicolaus boosted their price target on shares of Blueprint Medicines from $95.00 to $97.00 and gave the company a “buy” rating in a research note on Tuesday, January 9th. Four investment analysts have rated the stock with a sell rating, two have given a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $85.43.

Blueprint Medicines Stock Down 1.7 %

BPMC traded down $1.53 during mid-day trading on Thursday, reaching $90.73. 755,177 shares of the stock were exchanged, compared to its average volume of 764,408. The company has a 50 day moving average price of $90.73 and a two-hundred day moving average price of $78.51. The company has a debt-to-equity ratio of 1.60, a quick ratio of 3.66 and a current ratio of 3.76. The stock has a market capitalization of $5.55 billion, a PE ratio of -10.85 and a beta of 0.63. Blueprint Medicines Co. has a 1 year low of $43.89 and a 1 year high of $101.00.

Blueprint Medicines (NASDAQ:BPMC) last issued its quarterly earnings results on Thursday, February 15th. The biotechnology company reported ($1.82) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.04) by $0.22. The company had revenue of $71.96 million for the quarter, compared to the consensus estimate of $67.34 million. Blueprint Medicines had a negative net margin of 203.30% and a negative return on equity of 191.56%. The firm’s quarterly revenue was up 85.5% on a year-over-year basis. During the same period in the previous year, the firm earned ($2.65) EPS. As a group, research analysts anticipate that Blueprint Medicines Co. will post -5.41 EPS for the current year.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.